Tag: Lung Cancer

Modifiable risk‐attributable and age‐related burden of lung cancer in China, 1990–2019

There were limited studies on the quantification of the modifiable and nonmodifiable lung cancer burden over time in China . The potential effect of risk factor reduction on gains in life expectancy (LE) remains unknown . Tobacco use had the most robust impact on LE for both sexes (PGLE: 0.71 years for males and .19 years… Continue reading Modifiable risk‐attributable and age‐related burden of lung cancer in China, 1990–2019

Diagnostic follow‐up of indeterminate pulmonary nodules in the Medicare population

Management of indeterminate pulmonary nodules (IPNs) is associated with redistribution of lung cancer to earlier stages . The burden of IPN management in Medicare recipients was assessed . Excess rates of various procedures due to reported IPNs over 2 years of follow-up (chest CT, PET/PET-CT, bronchoscopy, needle biopsy, and surgical procedures) were estimated using multivariable… Continue reading Diagnostic follow‐up of indeterminate pulmonary nodules in the Medicare population

Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer

Abstract The improved survival outcomes of patients with non-small-cell lung cancer (NSCLC), largely owing to the improved control of systemic disease provided by immune-checkpoint inhibitors and novel targeted therapies, have highlighted the challenges posed by central nervous system (CNS) metastases as a devastating yet common complication, with up to 50% of patients developing such lesions… Continue reading Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer

Use of cancer vaccine after immunotherapy failure: a promising strategy for advanced NSCLC patients with secondary resistance to checkpoint inhibitors

Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Despite the significant outcomes achieved with immune checkpoint blockade (ICB), used alone or in combination with chemotherapy (CT), almost half of these patients do not initially respond to this strategy (primary resistance), and furthermore, a subset of patients who initially respond, later relapse… Continue reading Use of cancer vaccine after immunotherapy failure: a promising strategy for advanced NSCLC patients with secondary resistance to checkpoint inhibitors

[Articles] First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

At 35 months’ follow-up, the survival benefit of cemiplimab for patients with advanced non-small-cell lung cancer was at least as pronounced as at 1 year, affirming its use as first-line monotherapy for this population. Adding chemotherapy to cemiplimab at progression might provide a new second-line treatment for patients with advanced non-small-cell lung cancer.

A PI3K gene expression signature predicts for recurrence in early‐stage non–small cell lung cancer treated with stereotactic body radiation therapy (SBRT)

Early-stage non–small cell lung cancer (NSCLC) is treated with stereotactic body radiation therapy (SBRT) Although treatment is generally effective, a small subset of tumors will recur because of radioresistance . Preclinical studies suggested PI3K-AKT-mTOR activation mediates radiotherapy . This study sought to validate this finding in tumor samples from patients who underwent SBRt .

A PI3K gene expression signature predicts for recurrence in early‐stage non–small cell lung cancer treated with stereotactic body radiation therapy (SBRT)

Abstract Introduction Increasingly, early-stage non–small cell lung cancer (NSCLC) is treated with stereotactic body radiation therapy (SBRT). Although treatment is generally effective, a small subset of tumors will recur because of radioresistance. Preclinical studies suggested PI3K-AKT-mTOR activation mediates radioresistance. This study sought to validate this finding in tumor samples from patients who underwent SBRT for… Continue reading A PI3K gene expression signature predicts for recurrence in early‐stage non–small cell lung cancer treated with stereotactic body radiation therapy (SBRT)

Study may bring improved therapy to preselected lung cancer patients

New findings may lead to relapse-free treatment for a sizeable subgroup of lung cancer patients. In a study in mice, scientists have identified a biomarker that may help physicians select lung cancer patients who can be treated with a single antibody-based drug that is likely to bring about full remission, without cancer relapse.